Matthew S. Davids, MD, MMSc

Matthew S. Davids, MD, MMSc

Medical Oncology

Contact Information

Office Phone Number





617-632-6246 (new)


Matthew S. Davids, MD, MMSc

After obtaining an A.B. cum laude in chemistry at Harvard College, Dr. Davids completed his M.D. cum laude at Yale University School of Medicine. He served as an intern, resident, and assistant chief resident in internal medicine at New York-Presbyterian Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York City. He then completed his fellowship in hematology and oncology in Dana-Farber/Partners CancerCare, and a Masters in Medical Science (M.M.S.c.) at Harvard Medical School. He is an attending physician in the Division of Lymphoma, where he serves as the Director of Clinical Research, as well as Associate Director of the CLL Center. He is also an Associate Professor of Medicine at Harvard Medical School, and attends on the inpatient hematologic malignancies service at Brigham and Women's Hospital. Dr. Davids has an active translational research program in CLL and non-Hodgkin lymphoma, focusing on studying apoptosis (in particular Bcl-2 biology) in his laboratory, and leading clinical trials to evaluate novel therapeutic strategies in patients with CLL and other hematologic malignancies. Much of his work has focused on the clinical development of new therapeutic regimens in CLL utilizing combinations of targeted inhibitors of Bcl-2, B cell receptor pathway kinases, and other novel agents, as well as utilizing checkpoint blockade to enhance anti-tumor immunity in patients with hematologic malignancies who relapse post allogeneic hematopoietic cell transplantation.



Director, Clinical Research, Division of Lymphoma
Associate Professor of Medicine, Harvard Medical School


Center for Chronic Lymphocytic Lymphoma (CLL)
Stem Cell Transplantation
Lymphoma Program

Clinical Interests

Chronic lymphocytic leukemia, Lymphoma

Board Certification

  • Hematology, 2011
  • Internal Medicine, 2008
  • Medical Oncology, 2011


  • Dana-Farber/Partners CancerCare, Hematology/Oncology


  • New York-Presbyterian Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center, Internal Medicine

Medical School

  • Yale University School of Medicine


    • An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL. Blood Adv. 2024 Jun 11; 8(11):2861-2869. View in: Pubmed

    • Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison. Haematologica. 2024 Jun 01; 109(6):1866-1873. View in: Pubmed

    • The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival. Haematologica. 2024 May 30. View in: Pubmed

    • A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Adv. 2024 May 28; 8(10):2342-2350. View in: Pubmed

    • Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia. Blood Adv. 2024 Apr 23; 8(8):1992-2004. View in: Pubmed

    • Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: Pooled analysis of 5 clinical trials. Blood Adv. 2024 Apr 19. View in: Pubmed

    • Burden of Infection in Patients With and Without Secondary Immunodeficiency Disease Following Diagnosis of a Mature B Cell Malignancy. Clin Lymphoma Myeloma Leuk. 2024 Apr 10. View in: Pubmed

    • Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. J Clin Oncol. 2024 Jun 10; 42(17):2071-2079. View in: Pubmed

    • Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study. Blood Adv. 2024 Feb 27; 8(4):842-845. View in: Pubmed

    • Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL. Blood Adv. 2024 Feb 27; 8(4):832-841. View in: Pubmed

    • Therapeutic targeting of apoptosis in chronic lymphocytic leukemia. Semin Hematol. 2024 Apr; 61(2):109-118. View in: Pubmed

    • Overcoming Resistance in Chronic Lymphocytic Leukemia-Maybe Less Is More? Clin Cancer Res. 2024 02 01; 30(3):471-473. View in: Pubmed

    • First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2024 02 01; 30(3):506-521. View in: Pubmed

    • Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLL. Res Sq. 2024 Jan 16. View in: Pubmed

    • Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax. Haematologica. 2024 Jan 01; 109(1):186-199. View in: Pubmed

    • Functional cure reported in CLL. Blood. 2023 11 23; 142(21):1761-1763. View in: Pubmed

    • PI3Kd activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine. bioRxiv. 2023 Nov 16. View in: Pubmed

    • Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies. J Clin Invest. 2023 11 15; 133(22). View in: Pubmed

    • A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma. Ann Hematol. 2024 Jan; 103(1):185-198. View in: Pubmed

    • Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia. Blood Adv. 2023 10 10; 7(19):5877-5889. View in: Pubmed

    • Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia. Blood Adv. 2023 09 12; 7(17):4728-4737. View in: Pubmed

    • Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv. 2023 09 12; 7(17):4748-4759. View in: Pubmed

    • PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023 08 18; 22(1):138. View in: Pubmed

    • Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors. bioRxiv. 2023 Aug 03. View in: Pubmed

    • Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples. Blood. 2023 08 03; 142(5):421-433. View in: Pubmed

    • Management of Richter transformation. Clin Adv Hematol Oncol. 2023 08; 21(8):449-451. View in: Pubmed

    • Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial. Clin Cancer Res. 2023 07 05; 29(13):2385-2393. View in: Pubmed

    • Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Blood Adv. 2023 05 09; 7(9):1929-1943. View in: Pubmed

    • Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood. 2023 04 13; 141(15):1817-1830. View in: Pubmed

    • Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings. Blood. 2023 04 13; 141(15):1884-1888. View in: Pubmed

    • Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study. Clin Lymphoma Myeloma Leuk. 2023 07; 23(7):515-526. View in: Pubmed

    • Targeted engagement of ß-catenin-Ikaros complexes in refractory B-cell malignancies. bioRxiv. 2023 Mar 15. View in: Pubmed

    • In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities. Blood Cancer Discov. 2023 03 01; 4(2):150-169. View in: Pubmed

    • Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kd inhibitors. Blood Cancer J. 2023 02 02; 13(1):22. View in: Pubmed

    • A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia. 2023 04; 37(4):835-842. View in: Pubmed

    • Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma. Hemasphere. 2023 Feb; 7(2):e826. View in: Pubmed

    • Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome. Nat Med. 2023 01; 29(1):158-169. View in: Pubmed

    • Practical Management of Richter Transformation in 2023 and Beyond. Am Soc Clin Oncol Educ Book. 2023 Jan; 43:e390804. View in: Pubmed

    • MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncol. 2022 Oct; 18(33):3689-3699. View in: Pubmed

    • PI3K inhibitors in haematological malignancies. Lancet Oncol. 2022 08; 23(8):e364. View in: Pubmed

    • Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica. 2022 04 01; 107(4):984-987. View in: Pubmed

    • Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). Clin Cancer Res. 2022 02 15; 28(4):603-608. View in: Pubmed

    • Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. Blood. 2022 02 03; 139(5):686-689. View in: Pubmed

    • A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia. Am J Hematol. 2022 03 01; 97(3):E105-E109. View in: Pubmed

    • Integrated safety analysis of umbralisib, a dual PI3Kd/CK1e inhibitor, in relapsed/refractory lymphoid malignancies. Blood Adv. 2021 12 14; 5(23):5332-5343. View in: Pubmed

    • Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. 2021 12 01; 106(12):3219-3222. View in: Pubmed

    • Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. Cancer Discov. 2021 12 01; 11(12):3048-3063. View in: Pubmed

    • Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy. Am J Hematol. 2022 02 01; 97(2):E47-E51. View in: Pubmed

    • Venetoclax in Previously Treated Waldenström Macroglobulinemia. J Clin Oncol. 2022 01 01; 40(1):63-71. View in: Pubmed

    • A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. Leukemia. 2022 03; 36(3):723-732. View in: Pubmed

    • COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. Blood. 2021 11 04; 138(18):1768-1773. View in: Pubmed

    • Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States. J Manag Care Spec Pharm. 2021 Nov; 27(11):1532-1544. View in: Pubmed

    • IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kd inhibitor idelalisib. Haematologica. 2021 11 01; 106(11):2995-2999. View in: Pubmed

    • Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. Haematologica. 2021 11 01; 106(11):2845-2852. View in: Pubmed

    • Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. Transplant Cell Ther. 2022 01; 28(1):32.e1-32.e10. View in: Pubmed

    • Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol. 2021 10; 22(10):1391-1402. View in: Pubmed

    • Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies. Blood Adv. 2021 08 24; 5(16):3062-3065. View in: Pubmed

    • Twists and turns from "tumor in tumor" profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis. Cold Spring Harb Mol Case Stud. 2021 08; 7(4). View in: Pubmed

    • Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. Haematologica. 2021 08 01; 106(8):2251-2256. View in: Pubmed

    • BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Blood. 2021 06 24; 137(25):3495-3506. View in: Pubmed

    • Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021 06 10; 137(23):3212-3217. View in: Pubmed

    • The redox-senescence axis and its therapeutic targeting. Redox Biol. 2021 09; 45:102032. View in: Pubmed

    • Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. Clin Cancer Res. 2021 09 01; 27(17):4690-4695. View in: Pubmed

    • Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma. Pharmacoecon Open. 2021 Jun; 5(2):175-186. View in: Pubmed

    • Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemia. Leuk Lymphoma. 2021 10; 62(10):2342-2351. View in: Pubmed

    • miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors. Blood. 2021 05 06; 137(18):2481-2494. View in: Pubmed

    • Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 03 06; 397(10277):892-901. View in: Pubmed

    • Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy. EJHaem. 2021 May; 2(2):266-271. View in: Pubmed

    • A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. Haematologica. 2021 02 01; 106(2):651-654. View in: Pubmed

    • Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses. Am J Hematol. 2021 04 01; 96(4):E95-E98. View in: Pubmed

    • Highlights in chronic lymphocytic leukemia from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary. Clin Adv Hematol Oncol. 2021 Jan; 19 Suppl 4(1):21-23. View in: Pubmed

    • Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review. Crit Rev Oncol Hematol. 2021 Feb; 158:103212. View in: Pubmed

    • Serine-70 phosphorylated Bcl-2 prevents oxidative stress-induced DNA damage by modulating the mitochondrial redox metabolism. Nucleic Acids Res. 2020 12 16; 48(22):12727-12745. View in: Pubmed

    • A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay. Leuk Lymphoma. 2021 02; 62(2):478-481. View in: Pubmed

    • Idelalisib in indolent NHL - has it finally found its niche? Leuk Lymphoma. 2021 05; 62(5):1029-1030. View in: Pubmed

    • Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis. Clin Ther. 2020 10; 42(10):1955-1974.e15. View in: Pubmed

    • Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020 09 03; 136(10):1134-1143. View in: Pubmed

    • Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States. Pharmacoeconomics. 2020 09; 38(9):941-951. View in: Pubmed

    • Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020 08 25; 4(16):3977-3989. View in: Pubmed

    • A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. Leukemia. 2021 04; 35(4):1064-1072. View in: Pubmed

    • Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect® CLL Registry. EJHaem. 2020 Jul; 1(1):188-198. View in: Pubmed

    • A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020 06 11; 135(24):2182-2191. View in: Pubmed

    • Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts. Am J Hematol. 2020 08; 95(8):E199-E203. View in: Pubmed

    • BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte). Clin Cancer Res. 2020 07 15; 26(14):3514-3516. View in: Pubmed

    • Acalabrutinib for the initial treatment of chronic lymphocytic leukaemia. Lancet. 2020 04 18; 395(10232):1234-1236. View in: Pubmed

    • Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. Blood Adv. 2020 04 14; 4(7):1458-1463. View in: Pubmed

    • The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. Blood Adv. 2020 04 14; 4(7):1407-1418. View in: Pubmed

    • Systematic literature review of the global burden of illness of mantle cell lymphoma. Curr Med Res Opin. 2020 05; 36(5):843-852. View in: Pubmed

    • Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet. 2020 03 28; 395(10229):1078-1088. View in: Pubmed

    • Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 03 10; 4(5):858-867. View in: Pubmed

    • Breaking through BCL-2 inhibition in CLL. Blood. 2020 03 05; 135(10):709-711. View in: Pubmed

    • Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. Clin Cancer Res. 2020 05 01; 26(9):2096-2103. View in: Pubmed

    • Cutaneous eruptions from ibrutinib resembling epidermal growth factor receptor inhibitor-induced dermatologic adverse events. J Am Acad Dermatol. 2023 06; 88(6):1271-1281. View in: Pubmed

    • Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood. 2019 Nov 13; 134(Supplement_1):32. View in: Pubmed

    • BCL-2 Inhibitors, Present and Future. Cancer J. 2019 Nov/Dec; 25(6):401-409. View in: Pubmed

    • Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell. 2019 10 14; 36(4):369-384.e13. View in: Pubmed

    • Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood. 2019 10 03; 134(14):1132-1143. View in: Pubmed

    • Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clin Cancer Res. 2019 08 15; 25(16):5143-5155. View in: Pubmed

    • Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019 Aug; 6(8):e419-e428. View in: Pubmed

    • Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 12; 60(12):2931-2938. View in: Pubmed

    • Venetoclax: R-CHOP rocket booster? Blood. 2019 05 02; 133(18):1922-1924. View in: Pubmed

    • Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019 07 11; 134(2):111-122. View in: Pubmed

    • Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition. JAAD Case Rep. 2019 May; 5(5):401-405. View in: Pubmed

    • Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Adv. 2019 04 09; 3(7):1167-1174. View in: Pubmed

    • Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. Haematologica. 2019 11; 104(11):2258-2264. View in: Pubmed

    • Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. Lancet Haematol. 2019 Jan; 6(1):e38-e47. View in: Pubmed

    • Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. Br J Haematol. 2019 06; 185(5):961-966. View in: Pubmed

    • Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma. J Clin Oncol. 2018 Oct 25; JCO1800359. View in: Pubmed

    • Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. Leuk Lymphoma. 2019 05; 60(5):1312-1315. View in: Pubmed

    • A new triple threat to CLL. Blood. 2018 10 11; 132(15):1547-1548. View in: Pubmed

    • Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018 10 04; 3(19). View in: Pubmed

    • The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018 12 06; 132(23):2446-2455. View in: Pubmed

    • Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib. Leuk Lymphoma. 2019 02; 60(2):527-530. View in: Pubmed

    • The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood. 2018 09 20; 132(12):1248-1264. View in: Pubmed

    • Statins enhance efficacy of venetoclax in blood cancers. Sci Transl Med. 2018 06 13; 10(445). View in: Pubmed

    • Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res. 2018 09 15; 24(18):4371-4379. View in: Pubmed

    • Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018 07 01; 36(19):1973-1980. View in: Pubmed

    • Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation. Cancer Imaging. 2018 Apr 18; 18(1):13. View in: Pubmed

    • Risk of hepatitis B virus reactivation in patients treated with ibrutinib. Blood. 2018 04 26; 131(17):1987-1989. View in: Pubmed

    • Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect® CLL cohort study. Leuk Lymphoma. 2018 10; 59(10):2327-2335. View in: Pubmed

    • Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. Blood. 2018 03 08; 131(10):1073-1080. View in: Pubmed

    • Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018 04 12; 131(15):1704-1711. View in: Pubmed

    • Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 01; 19(1):65-75. View in: Pubmed

    • Safety profiles of novel agent therapies in CLL. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):354-357. View in: Pubmed

    • How should we sequence and combine novel therapies in CLL? Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):346-353. View in: Pubmed

    • Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. Clin Lymphoma Myeloma Leuk. 2018 02; 18(2):114-124.e2. View in: Pubmed

    • Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. Blood Adv. 2017 Nov 28; 1(25):2433-2443. View in: Pubmed

    • IGHV mutational status testing in chronic lymphocytic leukemia. Am J Hematol. 2017 Dec; 92(12):1393-1397. View in: Pubmed

    • Targeting BCL-2 in B-cell lymphomas. Blood. 2017 08 31; 130(9):1081-1088. View in: Pubmed

    • A complex case of ibrutinib treatment for a CLL patient on haemodialysis. Br J Haematol. 2018 06; 181(6):854-857. View in: Pubmed

    • Venetoclax for the treatment of patients with chronic lymphocytic leukemia. Future Oncol. 2017 Jun; 13(14):1223-1232. View in: Pubmed

    • Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. Eur J Heart Fail. 2017 05; 19(5):682-685. View in: Pubmed

    • Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States. BMC Cancer. 2017 03 16; 17(1):198. View in: Pubmed

    • The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. Curr Hematol Malig Rep. 2017 02; 12(1):11-19. View in: Pubmed

    • Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. 2017 10; 31(10):2075-2084. View in: Pubmed

    • Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. J Clin Oncol. 2017 Mar 10; 35(8):826-833. View in: Pubmed

    • Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017 Feb; 18(2):230-240. View in: Pubmed

    • Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017 02; 7(2):156-164. View in: Pubmed

    • Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol. 2017 Jan; 35(1):24-31. View in: Pubmed

    • Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. Blood. 2016 11 24; 128(21):2510-2516. View in: Pubmed

    • Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016 09 22; 128(12):1609-13. View in: Pubmed

    • FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia. Am J Hematol. 2016 10; 91(10):978-83. View in: Pubmed

    • Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53. View in: Pubmed

    • The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. View in: Pubmed

    • New Agents to Treat Chronic Lymphocytic Leukemia. N Engl J Med. 2016 06 02; 374(22):2186-7. View in: Pubmed

    • Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 07 14; 128(2):195-203. View in: Pubmed

    • Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016 05 20; 7:11589. View in: Pubmed

    • The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016 06 23; 127(25):3215-24. View in: Pubmed

    • The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. View in: Pubmed

    • Synchronous squamous cell carcinoma and diffuse large B-cell lymphoma of the head and neck: the odd couple. BJR Case Rep. 2016; 2(1):20150271. View in: Pubmed

    • A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol. 2016 Apr; 173(1):89-95. View in: Pubmed

    • Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. Cancer J. 2016 Jan-Feb; 22(1):34-9. View in: Pubmed

    • Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Jan 28; 374(4):311-22. View in: Pubmed

    • BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis. Clin Cancer Res. 2015 Nov 15; 21(22):5021-9. View in: Pubmed

    • Controversial fluorescence in situ hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. Br J Haematol. 2015 Sep; 170(5):694-703. View in: Pubmed

    • Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. Clin Cancer Res. 2015 Jul 15; 21(14):3160-9. View in: Pubmed

    • The evolving role of hematopoietic cell transplantation in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2015 Mar; 10(1):18-27. View in: Pubmed

    • The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015 Jul; 170(1):134-8. View in: Pubmed

    • Imatinib mesylate (Gleevec?) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial. Clin Exp Rheumatol. 2014 Nov-Dec; 32(6 Suppl 86):S-189-93. View in: Pubmed

    • Is Bcl-2 a valid target in the treatment of indolent non-Hodgkin lymphoma? Leuk Lymphoma. 2014 Dec; 55(12):2675-7. View in: Pubmed

    • Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014 Sep; 99(9):1499-508. View in: Pubmed

    • Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Future Oncol. 2014 May; 10(6):957-67. View in: Pubmed

    • Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2014 Apr; 12(4):224-9. View in: Pubmed

    • Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. JAMA Dermatol. 2014 Mar; 150(3):280-7. View in: Pubmed

    • Boldly Targeting Kinases without mutations. Blood. 2014 Feb 20; 123(8):1119-21. View in: Pubmed

    • Fatty intra-abdominal lymph nodes in chronic lymphocytic leukemia. Am J Hematol. 2014 Feb; 89(2):234-5. View in: Pubmed

    • Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013 Oct; 163(1):123-6. View in: Pubmed

    • Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma. 2013 Aug; 54(8):1823-5. View in: Pubmed

    • A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2013 Jun; 98(6):964-70. View in: Pubmed

    • Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia. Hematol Oncol Clin North Am. 2013 Apr; 27(2):329-39. View in: Pubmed

    • ABT-199: taking dead aim at BCL-2. Cancer Cell. 2013 Feb 11; 23(2):139-41. View in: Pubmed

    • Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol. 2013 Mar; 160(5):608-17. View in: Pubmed

    • Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Dec; 53(12):2362-70. View in: Pubmed

    • Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood. 2012 Oct 25; 120(17):3501-9. View in: Pubmed

    • BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res. 2012 Aug 15; 72(16):4193-203. View in: Pubmed

    • Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol. 2012 Sep 01; 30(25):3127-35. View in: Pubmed

    • Cell Trafficking in Chronic Lymphocytic Leukemia. Open J Hematol. 2012; 3(S1). View in: Pubmed

    • Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women. Breast Cancer Res Treat. 2011 Aug; 129(1):185-90. View in: Pubmed

    • Serum free light chain analysis. Am J Hematol. 2010 Oct; 85(10):787-90. View in: Pubmed

    • The molecular pathogenesis of myelodysplastic syndromes. Cancer Biol Ther. 2010 Aug 15; 10(4):309-19. View in: Pubmed

    • Medical management of radiation victims in the United States. Health Phys. 2010 Jun; 98(6):833-7. View in: Pubmed

    • Assessing surge capacity for radiation victims with marrow toxicity. Biol Blood Marrow Transplant. 2010 Oct; 16(10):1436-41. View in: Pubmed

    • Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma. J Clin Oncol. 2009 Sep 10; 27(26):e97-100. View in: Pubmed

    • Prevalence of BRCA1 and BRCA2 mutations in Jewish women with triple negative breast cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):22002. View in: Pubmed

    • STK25 is a candidate gene for pseudopseudohypoparathyroidism. Genomics. 2001 Sep; 77(1-2):2-4. View in: Pubmed


    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Directions

    Dana-Farber Cancer Institute

    Location Avtar

    Dana-Farber Cancer Institute

    450 Brookline Avenue Boston, MA 02215
    Get Direction
    42.3374, -71.1082

    Ratings and Comments

    Matthew S. Davids, MD, MMSc

    About Our Ratings

    Physician Star Rating Comment Block